Ph.D., Chief Scientific Officer, Inivata Ltd.
Nitzan trained in Physics and Systems Biology at the Weizmann Institute of Science. He joined Rosetta Genomics, where he was head of Computational Biology and led development of molecular diagnostic tests now offered commercially for clinical use. Since 2009 he is a group leader at the Cancer Research UK Cambridge Institute, University of Cambridge. His research group combines molecular technologies and genomic approaches to develop new diagnostic strategies. Their work on applications of circulating tumour DNA (ctDNA) for personalised cancer diagnostics led to the creation of Inivata Ltd, to bring the potential of ctDNA into clinical use. As co-founder and CSO of Inivata, he is responsible for managing the scientific and technology pipeline and overseeing research and development activities. Nitzan was awarded the CRUK Future Leaders in Cancer Research prize and the British Association for Cancer Research Translational Research Award (2013), and the Foulkes Medal (2015).
Targeted Deep Sequencing of Circulating Tumor DNA
ctDNA can support the clinical management of cancer patients. What are some methods for targeted deep sequencing of cell-free DNA? What are new platforms that have been optimized for high sensitivity detection of actionable and monitoring mutations in plasma, and validated for clinical use?
Session Abstract – PMWC 2017 Silicon Valley
Session Synopsis: Recent technological advances have ushered in a new generation of non-invasive molecular applications making it feasible to reliably detect and quantify circulating tumor DNA (ctDNA). This session will review the current technologies being employed, discuss clinical applications of ctDNA and provide examples of using both quantitative and qualitative assessment of ctDNA in the clinical setting.